PharmaLex furthers its clinical and regulatory reach
Merger with Phlexglobal expands provider’s technological capabilities.
PharmaLex Group, a provider of specialized services for the pharma, biotech and medtech industries, has merged with technology and services organization for clinical and regulatory solutions, Phlexglobal.
Phlexglobal offers its electronic Trial Master File platform (PhlexTMF) and services to a plethora of global life sciences companies and artificial intelligence (AI)-enabled automation solutions that allow clients to benefit from existing clinical and regulatory training models.
“We are delighted to welcome the Phlexglobal team to the PharmaLex Group, and the opportunity to continue our commitment to innovation by further expanding our technology-enabled service solutions portfolio with the addition of Phlexglobal’s capabilities for eTMF technology and services, as well as their state-of-the-art regulatory operations and automation technologies,” said Thomas Dobmeyer, PharmaLex CEO, in a Jan. 25, 2022 press release. “The merger enables us to further our goal of becoming a technology-enabled solution provider, and at the same time increasing operational excellence and efficiency through our global subject matter expertise.”
Source: PharmaLex
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
